Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$308K Sell
7,210
-6
-0.1% -$268 0.14% 93
2026
Q1
$348K Buy
7,216
+5
+0.1% +$233 0.18% 85
2025
Q4
$349K Sell
7,211
-415
-5% -$20.6K 0.17% 87
2025
Q3
$360K Buy
7,626
+60
+0.8% +$2.9K 0.17% 87
2025
Q2
$366K Buy
7,566
+135
+2% +$6.9K 0.2% 85
2025
Q1
$412K Buy
7,431
+305
+4% +$16.5K 0.24% 78
2024
Q4
$344K Buy
7,126
+580
+9% +$29.5K 0.22% 86
2024
Q3
$377K Buy
6,546
+745
+13% +$40.2K 0.25% 79
2024
Q2
$281K Buy
5,801
+535
+10% +$25.8K 0.21% 88
2024
Q1
$256K Buy
5,266
+226
+4% +$11K 0.2% 91
2023
Q4
$251K Buy
+5,040
New +$246K 0.2% 89

Other funds holding SNY

Wynn Capital's SNY Position: Q2 2026 in Review

Wynn Capital reduced its Sanofi (SNY) stake by 0.08% in Q2 2026, selling an estimated $268 and leaving 7,210 shares worth $308K. The position accounts for 0.14% of the portfolio, ranked #93.

Wynn Capital first reported a position in SNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $412K in Q1 2025. 272 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • Wynn Capital held 7,210 shares of Sanofi worth $308K as of Q2 2026.
  • Wynn Capital sold 6 Sanofi shares in Q2 2026, an estimated $268.
  • Sanofi made up 0.14% of Wynn Capital's portfolio in Q2 2026, its #93 holding.
  • Wynn Capital first reported a position in Sanofi in Q4 2023 and has held it in 11 quarters since.
  • Wynn Capital's Sanofi position peaked at $412K in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on Wynn Capital's 13F filing for Q2 2026, filed 8 Jul 2026.